BioStock Investor Meeting: Interview with Idogen
In connection with BioStock Investor Meeting in Stockholm, BioStock took the opportunity to interview Christina Herder, Idogen’s newly appointed interim CEO. In addition to telling us about the upcoming phase I/IIa study with the main candidate IDO8, Herder also discussed the potential of the company’s other two projects, IDO AID and IDO T.
See the interview with Idogen’s interim CEO Christina Herder below.
